findmyKOL

Paul Richardson, MD

Enriched profile

Clinical Program Leader and Director of Clinical Research, Jerome Lipper Multiple Myeloma Center; RJ Corman Professor of Medicine, Harvard Medical School; Institute Physician, Dana-Farber Cancer Institute · Dana-Farber Cancer Institute

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Boston, MA · Northeast · United StatesSpecialtyHematology / OncologyFocusMultiple Myeloma Research and Treatments+4
Active KOLfindmyKOL type: NationalLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2005–2007

Paul Richardson is Clinical Program Leader and Director of Clinical Research, Jerome Lipper Multiple Myeloma Center; RJ Corman Professor of Medicine, Harvard Medical School; Institute Physician, Dana-Farber Cancer Institute at Dana-Farber Cancer Institute. OpenAlex indexes 2,062 publications with 132,822 citations (h-index 172); ClinicalTrials.gov lists 18 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Hematology / Oncology profiles in the findmyKOL directory. Clarivate lists Paul Richardson as a Highly Cited Researcher (Clinical Medicine, 2019-2024).

Data verified 25 Aug 2026

Overview

Updated 13 Oct 2026

Paul G. Richardson, MD, is Clinical Program Leader and Director of Clinical Research, Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute (Harvard Medical School affiliate). The public record shows 2,062 publications with 132,822 citations (h-index 172), centered on Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Peptidase Inhibition and Analysis. It also documents an investigator role on 18 registered clinical trials, industry payments reported by 24 companies, 1 NIH-funded awards (2005–2007).

  • Most recent indexed publication: 2026 · European journal of haematology
  • Top research focus: Multiple Myeloma Research and Treatments
  • 18 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 24 companies

Generated from the cited public record · current as of 13 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Multiple Myeloma14 trialsRecurrence3 trialsHepatic Veno-Occlusive Disease2 trialsLung Cancer (NSCLC/SCLC)1 trialBladder / Urothelial Cancer1 trialKidney Cancer / RCC1 trialOvarian / Gynecologic Cancer1 trialHead & Neck Cancer1 trialSarcoma1 trialKidney Neoplasms1 trialCentral Nervous System Neoplasms1 trialComa1 trialTesticular Germ Cell Tumor1 trialNervous System Neoplasms1 trial

Research focus

OpenAlex concept fingerprint
Multiple Myeloma Research and TreatmentsProtein Degradation and InhibitorsPeptidase Inhibition and AnalysisCancer Treatment and PharmacologyUbiquitin and proteasome pathways

Drugs & molecules

across trials, industry payments and publications
Revlimidgeneric · LenalidomideClinical trials5Industry payments3Publications21Defiteliogeneric · DefibrotideClinical trials3Industry payments5Publications6DexamethasoneClinical trials8Industry payments—Publications34Sarclisageneric · IsatuximabClinical trials—Industry payments34Publications5BortezomibClinical trials7Industry payments—Publications19Darzalexgeneric · DaratumumabClinical trials—Industry payments1Publications13Xpoviogeneric · SelinexorClinical trials—Industry payments9Publications4Ninlarogeneric · IxazomibClinical trials—Industry payments1Publications4Emplicitigeneric · ElotuzumabClinical trials—Industry payments1Publications3PerifosineClinical trials3Industry payments—Publications1Kyprolisgeneric · CarfilzomibClinical trials—Industry payments2Publications1Blenrepgeneric · Belantamab mafodotinClinical trials—Industry payments1Publications1

Works with

trial sponsors and companies reporting payments
Genzyme CorporationClinical trials—Industry payments37GlaxoSmithKline, LLC.Clinical trials—Industry payments24Celgene CorporationClinical trials—Industry payments18E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments16Abbvie Inc.Clinical trials—Industry payments13Karyopharm Therapeutics Inc.Clinical trials—Industry payments9Adaptive Biotechnologies CorporationClinical trials—Industry payments6Dana-Farber Cancer InstituteClinical trials6Industry payments—Jazz Pharmaceuticals Inc.Clinical trials—Industry payments6Regeneron Pharmaceuticals, Inc.Clinical trials—Industry payments6Sanofi-Aventis U.S. LLCClinical trials—Industry payments5AEterna ZentarisClinical trials3Industry payments—AstraZeneca UK LimitedClinical trials—Industry payments3Amgen Inc.Clinical trials—Industry payments2Janssen Biotech, Inc.Clinical trials—Industry payments2Jazz PharmaceuticalsClinical trials2Industry payments—BioLineRx USA, Inc.Clinical trials—Industry payments1Epizyme, Inc.,Clinical trials—Industry payments1Gamida Cell Inc.Clinical trials—Industry payments1GlaxoSmithKlineClinical trials1Industry payments—Infinity Pharmaceuticals, Inc.Clinical trials1Industry payments—Janssen Research & Development, LLCClinical trials1Industry payments—Legend Biotech USA Inc.Clinical trials—Industry payments1Menarini Silicon Biosystems, Inc.Clinical trials—Industry payments1Oncopeptides ABClinical trials1Industry payments—Paul Richardson, MDClinical trials1Industry payments—Pfizer Inc.Clinical trials—Industry payments1PharmaMarClinical trials1Industry payments—Prolexys PharmaceuticalsClinical trials1Industry payments—Secura Bio, Inc.Clinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
2,062publications

Distinct works indexed by OpenAlex, matched via ORCID; 83 in PubMed.

132,822citations

Total citations across indexed works.

172h-index

Hirsch index (OpenAlex). i10-index 886.

Clinical & industry

trials, payments and federal funding
18clinical trials

Investigator role on registered studies.

View trials ↓
24companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
1NIH grants · 2005–2007

Federally funded research awards.

View funding ↓

Public positions

sourced statements on record

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 13 Oct 2026

Listed as an investigator on 18 registered studies on ClinicalTrials.gov. The most recent:

All 18 trial records: search, sort and filter.Explore →

Industry payments

Updated 13 Oct 2026

24 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 47 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    28.6%
    Thalidomide Analog28.6%
    Revlimid71%Pomalyst30%
    Part D≥42 patients

  • Sensory organs

    24.3%
    Other antiinfectives21%
    Chlorhexidine Gluconate100%
    Part D≥57 patients
    Corticosteroid3.3%
    Dexamethasone100%
    Part D≥12 patients

  • Dermatology

    18.8%
    Azole Antifungal18.8%
    Clotrimazole100%
    Part D≥48 patients
All 5 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)95.2% facility · 4.8% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 13 Oct 2026

1 NIH research award on record, funded 2005–2007 per NIH RePORTER. The latest:

Publications

Updated 13 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 83 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
    4,876 citations2014
    doi.org ↗
  2. 02
    International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
    3,004 citations2016
    doi.org ↗
  3. 03
    BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
    2,847 citations2011
    doi.org ↗
  4. 04
    A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
    2,642 citations2003
    doi.org ↗
  5. 05
    International uniform response criteria for multiple myeloma
    2,640 citations2006
    doi.org ↗
All 2,062 cited works: search, sort and filter.Explore →

Network

Updated 13 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Kenneth C. Anderson1060Nikhil C. Munshi439Teru Hideshima419Jacob P. Laubach412Noopur Raje299Constantine S. Mitsiades269Sagar Lonial256Dharminder Chauhan254Philippe Moreau222Meletios Α. Dimopoulos219Jesús F. San Miguel206Irene M. Ghobrial205Robert Schlossman198Yu‐Tzu Tai196María‐Victoria Mateos134Sundar Jagannath132Andrew J. Yee120Robert Z. Orlowski110Pieter Sonneveld106Thierry Façon105Xavier Leleu96Andrzej Jakubowiak91Nicholas Mitsiades90Shaji Kumar90Michèle Cavo90S. Vincent Rajkumar88Peter M. Voorhees88Klaus Podar87Omar Nadeem82Antonio Palumbo81David S. Siegel79Helgi van de Velde78Albert Oriol77Nizar J. Bahlis76Mariateresa Fulciniti73Ivan Špıčka68Ajai Chari67Saad Z. Usmani67Enrique M. Ocio66Joan Bladé66

Online presence

Updated 13 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Other

    dana-farber.org/find-a-doctor/paul-g-richardson

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • Other

    myeloma.org/videos/ash-2016-multiple-myeloma-overview-dr-paul-richardson

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →myeloma.org ↗
  • X / Twitter

    x.com/DanaFarber/status/1978502379562483805

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗

Mentions by others

where others cite or feature them
  • X / Twitter

    Dana-Farber (official @DanaFarber X account) congratulating Paul Richardson, MD on the Joseph Michaeli Award

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com ↗
  • X / Twitter

    Lymphoma, Leukemia & Myeloma Congress (@llmcongress X account) announcing Richardson's keynote and Michaeli Award

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com ↗
  • LinkedIn

    Dana-Farber LinkedIn post referencing IMF naming Dr. Richardson for the Kyle Lifetime Achievement Award

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 13 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments

Highly Cited Researcher

Clarivate's annual list, by award category and year
  • Clinical Medicine
    201920202021202220232024
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.